Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)

Clinical trial NCT07023432 · RECRUITING

Trial details

NCT number: NCT07023432
Sponsor: M.D. Anderson Cancer Center
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Active Surveillance Clear Cell Renal Cell Carcinoma

Start date: 2025-11-17
Primary completion: 2028-04-14
Enrollment: 78

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.